NASDAQ:BIVI BioVie (BIVI) Stock Price, News & Analysis $1.48 +0.04 (+2.78%) Closing price 04:00 PM EasternExtended Trading$1.48 +0.00 (+0.07%) As of 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About BioVie Stock (NASDAQ:BIVI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BioVie alerts:Sign Up Key Stats Today's Range$1.42▼$1.5050-Day Range$1.20▼$1.6652-Week Range$1.06▼$12.10Volume114,184 shsAverage Volume94,615 shsMarket Capitalization$11.16 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview BioVie Inc. is a clinical‐stage biopharmaceutical company focused on developing novel therapies for chronic liver diseases and associated neurological complications. The company’s research and development efforts center on candidates designed to address serious unmet medical needs in hepatic encephalopathy and other liver‐related disorders. BioVie advances its pipeline through controlled clinical trials and regulatory interactions in North America. The company’s lead product candidate, BIV201, is undergoing Phase 2 clinical evaluation for the treatment of hepatic encephalopathy, a life‐threatening condition marked by elevated neurotoxins in patients with advanced liver disease. BIV201 is being assessed for its potential to reduce ammonia levels and improve cognitive function, with data from early studies indicating a favorable safety profile and signs of clinical benefit. In addition to its lead program, BioVie maintains exploratory efforts targeting other chronic liver indications, including primary biliary cholangitis and alcohol‐associated liver disease. These preclinical and early‐stage candidates leverage the company’s expertise in small‐molecule modulation of metabolic and inflammatory pathways, with the goal of expanding treatment options for patients who currently have limited therapeutic choices. Headquartered in Emeryville, California, BioVie was founded with the mission of transforming the management of liver diseases through innovative drug development. The company operates in collaboration with leading academic institutions and clinical research organizations across the United States and Canada. Guided by an experienced executive team with backgrounds in biotechnology and pharmaceutical development, BioVie is committed to advancing its portfolio toward late‐stage clinical trials and eventual regulatory approval.AI Generated. May Contain Errors. Read More BioVie Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks17th Percentile Overall ScoreBIVI MarketRank™: BioVie scored higher than 17% of companies evaluated by MarketBeat, and ranked 804th out of 867 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingBioVie has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageBioVie has only been the subject of 1 research reports in the past 90 days.Read more about BioVie's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of BioVie is -0.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioVie is -0.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioVie has a P/B Ratio of 0.71. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.53% of the float of BioVie has been sold short.Short Interest Ratio / Days to CoverBioVie has a short interest ratio ("days to cover") of 1.61, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioVie has recently increased by 6.90%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBioVie does not currently pay a dividend.Dividend GrowthBioVie does not have a long track record of dividend growth. News and Social Media3.3 / 5News Sentiment0.25 News SentimentBioVie has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for BioVie this week, compared to 2 articles on an average week.Search Interest2 people have searched for BIVI on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows3 people have added BioVie to their MarketBeat watchlist in the last 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, BioVie insiders have not sold or bought any company stock.Percentage Held by Insiders0.90% of the stock of BioVie is held by insiders.Percentage Held by Institutions4.59% of the stock of BioVie is held by institutions.Read more about BioVie's insider trading history. Receive BIVI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioVie and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BIVI Stock News HeadlinesJoin BioVie's Exclusive Live Investor Webinar and Q and A Session on June 2May 27 at 8:00 AM | globenewswire.comBioVie completes enrollment in Phase 2 Long COVID trialMay 26 at 9:15 AM | proactiveinvestors.comI was right about SpaceXJeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,000%. Now he says SpaceX is shaping up to be the biggest IPO of the decade - and three key milestones just confirmed it. In the past 21 days: SpaceX crossed 10,000 active satellites, Elon filed confidential IPO paperwork with the SEC, and another rocket launched 25 more satellites. Two-thirds of every satellite in orbit now belongs to one company. The public filing could drop any day.May 27 at 1:00 AM | Brownstone Research (Ad)BioVie Announces Full Enrollment of the ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVIDMay 26 at 8:00 AM | globenewswire.comContrasting Cassava Sciences (NASDAQ:FLNA) & BioVie (NASDAQ:BIVI)May 25 at 5:01 AM | americanbankingnews.comBioVie completes final patient visit in Parkinson's drug trialMay 19, 2026 | proactiveinvestors.comBioVie Announces Completion of Phase 2 SUNRISE-PD Trial in Early-Stage Parkinson’s DiseaseMay 18, 2026 | markets.businessinsider.comBioVie Inc. Completes Final Patient Visit in SUNRISE-PD Phase 2 Trial for Bezisterim in Early-Stage Parkinson's DiseaseMay 18, 2026 | quiverquant.comQSee More Headlines BIVI Stock Analysis - Frequently Asked Questions How have BIVI shares performed this year? BioVie's stock was trading at $1.16 on January 1st, 2026. Since then, BIVI shares have increased by 27.6% and is now trading at $1.48. How were BioVie's earnings last quarter? BioVie Inc. (NASDAQ:BIVI) released its earnings results on Monday, May, 11th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.73) by $0.03. When did BioVie's stock split? Shares of BioVie reverse split on Monday, July 7th 2025.A 1-10 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Sunday, July 6th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are BioVie's major shareholders? BioVie's top institutional investors include Renaissance Technologies LLC (0.90%). Insiders that own company stock include Steve Gorlin and Cuong V Do. View institutional ownership trends. How do I buy shares of BioVie? Shares of BIVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of BioVie own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioVie investors own include ARMOUR Residential REIT (ARR), AGNC Investment (AGNC), Hon Hai Precision Industry Co., Ltd. Sponsored GDR (HNHPF), Main Street Capital (MAIN), Ares Capital (ARCC) and PIMCO Dynamic Income Fund (PDI). Company Calendar Last Earnings5/11/2026Today5/27/2026Investor update6/02/2026Fiscal Year End6/30/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (29m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 BIVI's financial health is in the Red zone, according to TradeSmith. BIVI has been in this zone for over 29 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BIVI CIK1580149 Webbioviepharma.com Phone(775) 888-3162FaxN/AEmployees10Year Founded2013Profitability EPS (Trailing Twelve Months)($2.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$17.54 million Net MarginsN/A Pretax MarginN/A Return on Equity-101.15% Return on Assets-90.18% Debt Debt-to-Equity RatioN/A Current Ratio9.96 Quick Ratio9.96 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.07 per share Price / Book0.71Miscellaneous Outstanding Shares7,540,000Free Float7,474,000Market Cap$11.16 million OptionableNo Data Beta0.72 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:BIVI) was last updated on 5/27/2026 by MarketBeat.com Staff. From Our PartnersThe 1934 playbookIn 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...American Alternative | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...Porter & Company | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioVie Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioVie With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
